TFII.TO -1.7C 0.13MU -51.63CRWD 5.64PANW 6.15SNOW -4.82V -0.14MAL.TO -0.14
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.21
+0.20 (0.78%)
as of Aug 3, 2026, 1:30:21 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
TOP PICK

Pfizer Inc(PFE)

Dec 05, 2005
Owns this in tandem with Teva (TEVA-Q). This is their value company. Have had a lot of problems but feels this is already in the stock. Selling at about 10 or 11 X next year's earnings. Yield about 3.5%. Expect there will be an nice kick out of the stock when some of the problems are settled.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$21.35

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 28, 2005
The pharmaceutical area has been very difficult for a long time. They face an FDA which has been very difficult. Cheap from a historical point of view. Throw up tons of free cash flow. P/E is in the range of 10/12 X. It's a long road ahead for them. Thinks Pfizer's pipeline is being under valued. Bad news is already built into the stock.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$21.59

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 23, 2005
(A Top Pick Sept 7/05. Down 18%.) His model is still showing a 50% upside. Still likes.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$21.64

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 22, 2005
There are law suits coming at these companies from different directions. Merck (MRK-N) just got hit with a massive lawsuit in Texas and this has put a big pall over the industry. However, the demograpohics in this industry are fabulous. This one is the biggest in the industry and they have a huge amount of cash on their balance sheet. The options are very cheap and not a bad way to go.
Photo of Richard CroftRichard Croft
No
Unlock Rating
$21.38

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 14, 2005
Not a fan of the big drug companies. They are under tremendous pressure. One of the biggest expenses the US has to grapple with is health care, so the government is now on the side of the consumer, so it would be very hard for big pharma to have the kind of margins and sales growth they used to have.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$22.25

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 02, 2005
The overall pharmaceutical industry has had a tough time. Yields almost 4%. Trading at close to 10 X earnings. This industry has had bad direction from the FDA. Great balance sheet and lots of free cash flow.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$21.60

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 26, 2005
The ethical drug companies continue to have a very difficult time. You are seeing a classic compression of the price/earnings multiple. The growth rate of these companies has gone from 25% growth to almost 0% growth in the last 3/4 years.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$21.06

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Pfizer Inc(PFE)

Oct 20, 2005
There's a possibility for it to go to $19.65 at which time he will buy more. It's in a bottoming process. Looking for the new earnings estimates to come in during the next few weeks. His model price is $36 which is a 51% differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$21.90

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 13, 2005
Have too many suits hanging over him for his tastes. Doesn't like a sector where there's a lot of potential for a lot of nasty surprises.
Photo of Ross HealyRoss Healy
No
Unlock Rating
$24.50

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 27, 2005
Doesn't feel the FDA hasn't done a good job, but that is changing. Feels the pharmaceutical industry's pipeline is being valued at a very low multiple. At one of the cheapest levels in the last 10 years. Yields about 2.5/3%. Throws off tons of free cash flow. A long term story.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$24.80

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 22, 2005
Drug stars such as Pfizer (PFE-N) Merck (MRK-N), etc. are attractively valued but are clearly out of favour. They have great long term track records and are in strong financial positions, however, there is a lack of predictability regarding the science. Doesn't like the cash flow dynamics where they spend billions up front with no sure win ahead. Litigation risks.
Photo of James Cole, BA, CFAJames Cole, BA, CFA
Owned
Unlock Rating
$25.25

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 21, 2005
Still likes and is a believer in this company. His model price is 50% above the current price, but doesn't know when that value will be recognized.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.31

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 20, 2005
No advantage to be in this stock. The whole drug area has changed in the last few years and they are not as strong as they once were. The market seems to be moving more to generics.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$25.40

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 07, 2005
His model price is $37.65, an 46% differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.51

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 31, 2005
Very cheap on the numbers, but they have a patent issue on their largest drug, Lippitor. If they lost Lippitor, you would be looking at a stock below $20 overnight. There's a lot of risk in the name.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$25.48

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
Showing 646 to 660 of 885 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG 3.18$148.69
SLB 0.68$49.59
SHEL 1.47$91.98
AAPL -24.52$308.91
AMZN 36.08$271.58

Today's Top Picks

TFII.TO -1.7$13.38
C 0.13$132.45
MU -51.63$823.03
CRWD 5.64$190.86
PANW 6.15$331.83

Popular Articles

Latest Sell Signals

AAPL -24.52$308.91
AAPL -24.52$308.91
AAPL -24.52$308.91
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like